Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma
Source : https://doi.org/10.1080/14712598.2021.1884677
ABSTRACT Patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) require further treatment options, especially in cases that cannot tolerate stem cell transplant or cytotoxic chemotherapy. CD19 has emerged as an attractive target in B-cell malignancy and is the subject of several therapeutic strategies.
-
Mark FeslerApril 03, 2021Tafa and rev individually have low but respectable single agent activity in dlbcl that is enhanced significantly in combination and the dor is very exciting in a subset of patients with long term followup